Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)

Inclusion Criteria * Patients must have untreated cervical biopsy-proven, CIN 2/3 ectocervical lesion(s). * Patients must have satisfactory colposcopy with visualization of the entire transformation zone or a negative endocervical curettage if colposcopy is unsatisfactory. * Patients must be high-risk HPV+ as determined by commercially available DNA hybridization test which tests for 13 high-risk HPV types. * All Patients must have a histologic diagnosis of CIN 2,3 cervical lesion(s) confirmed by a study pathologist within past 10 weeks. * Patients must have signed an approved informed consent. * Patients of childbearing potential must have a negative urine pregnancy test within 7 days prior to the study entry and be practicing an effective form of contraception. * Patients must be at least 18 years of age based on previous and current cervical cancer screening guidelines. * Patients must be fluent in speaking English or Spanish. Exclusion Criteria * Patients with unsatisfactory colposcopy\* (unable to visualize entire transformation zone) or evidence of endocervical disease defined as CIN 2/3 diagnosed on endocervical curettage. \*Patients with unsatisfactory colposcopy but negative endocervical curettage are eligible * Patients with a history of invasive cervical cancer * Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancers are excluded if there is any evidence of other malignancy being present within the last five ye…